Cyproheptadine inhibits in vitro and in vivo lung metastasis and drives metabolic rewiring.

ABSTRACT:

Background

Non-small cell lung cancer (NSCLC) accounts for 81% of lung cancer cases, among which over 47% presented with distant metastasis at the time of diagnosis. Despite the introduction of targeted therapy and immunotherapy, enhancing the survival rate and overcoming the development of resistance remain a big challenge. Thus, it is crucial to find potential new therapeutics and targets that can mitigate lung metastasis and investigate its effects on biomarkers, such as cellular metabolomics. In the current study, we investigated the role of cyproheptadine (CPH), an FDA-approved anti-histamine drug in lung metastasis in vitro and in vivo.

Methods and results

CPH showed potent cytotoxicity on different lung cancer cell lines in vitro. Moreover, CPH decreased invasion and

SUBMITTER: Shannar A 

PROVIDER: S-EPMC11551078 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature